Since 1987, Oxford University Innovation has been responsible for creating spinout companies based on academic research generated within and owned by the University of Oxford, and in recent years has spun out 15-20 new companies every year.
Over £2.5bn in external investment has been raised by Oxford University Innovation spinouts since 2010, and ten of our current portfolio are currently listed in London and New York.
The creation of new spinout companies, most of which are listed below, also channels millions of pounds back into University research, benefits local economic development and has created many new jobs in the region.
Intelligent Ultrasound develops and sells products and services that make medical ultrasound imaging a more effective diagnostic tool and help hospitals provide a better quality, more consistent ultrasound imaging service for their patients.
Incorporated in July 2012
Origin: Oxford University, Institute of Biomedical Engineering
Controlling insects that spread disease.
Incorporated in August 2002
Origin: Oxford University, Department of Zoology
Develop technologies that miniaturise fluid handling to accelerate drug discovery.
Incorporated in September 2016
Origin: Oxford University, Department of Pathology
Developing a novel cancer immunotherapy discovered through a collaboration between Ludwig Cancer Research and Professor Vincenzo Cerundolo, the director of the MRC Human Immunology Unit within the University of Oxford’s Weatherall Institute of Molecular Medicine.
Incorporated in July 2015
Origin: Oxford University, Radcliffe Department of Medicine
Company developing a new gene therapy products for the treatment of rare diseases.
Incorporated in April 2023
Origin: Oxford University, Paediatrics
First commercial producer of sustainable, guilt-free meat.
Incorporated in December 2019
Origin: Oxford University, Institute of Biomedical Engineering
A biotechnology company formed to research and develop novel medicines from natural sources for the treatment of immune-mediated and inflammatory diseases.
Incorporated in November 2010
Origin: Oxford University, Department of Biochemistry
Work with major marketing insights companies in order to develop their marketing products.
Incorporated in December 2020
Origin: Oxford University, Sir William Dunn School of Pathology
Developing small-molecule drugs targeting cancer-linked disordered proteins.
Incorporated in March 2024
State-of-the-art machine learning technology for autonomous vehicles and traffic modeling applications. Latent Logic was acquired by Waymo in December 2019.
Incorporated in February 2018
Origin: Oxford University, Department of Computer Science
Contact: Adrian Coles
LiliumX uses a unique protein technology platform to facilitate scalable discovery of first-in-class bispecific biologics
Incorporated in May 2021
Origin: Oxford University, Department of Biochemistry
DNA assembly.
Incorporated in July 2019
Origin: Oxford University
LitHits is a novel way to encourage people to read and engage with literature through their mobile phone via the LitHits app.
Incorporated in October 2020
Origin: Oxford University, Faculty of English Language and Literature
3D laser spectrometer and single shot hyperspectral imaging.
Incorporated in January 2020
Origin: Oxford University, Department of Physics
Contact: Steve Silvey
Navetas is a UK based technology company delivering cloud-based energy monitoring and smart data analytics for the connected home.
Incorporated in November 2008
Origin: Oxford University, Department of Engineering Science
Optical neural networks.
Incorporated in January 2022
Origin: Oxford University, Department of Physics
Development and commercialisation of quantum physics, acceleration and optimisation software for intelligent computational R&D.
Incorporated in May 2019
Origin: Oxford University, Department of Physics
Modelling the global economy for a sustainable future
Incorporated in September 2024
Origin: Oxford University, Smith School of Enterprise & Environment
A novel cancer cell therapy company, delivering tumour-targeted expression of anti-cancer biologics.
Incorporated in October 2018
Origin: Oxford University, Sir William Dunn School of Pharmacology
MatchBio's technology can improve the function of antigen receptors, for example by tuning their antigen sensitivity of their existing products.
Incorporated in August 2023
Origin: Oxford University, Sir William Dunn School of Pathology
